{"relation": [["", "STARTED", "COMPLETED", "NOT COMPLETED", "Physician Decision", "Lost to Follow-up"], ["TDF/FTC +/- TMC125 +/- DRV/Rtv", "23", "21", "2", "1", "1"]], "pageTitle": "A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment). - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00534352?sect=X0125&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 4, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989790.89/warc/CC-MAIN-20150728002309-00291-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 881384298, "recordOffset": 881367904, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Period 1: \u00a0 Treatment A: TMC125 + TDF/FTC Participant Flow for 4 periods In the first part of the trial (Days 1-14), all subjects received TMC125 400 mg once daily (qd) in combination with fixed dose combinations (FDC) of tenofovir disoproxil (TDF)/emtricitabine (FTC) 300/200 mg qd(Truvada\u00ae) for 14 days (Treatment A: TMC125 + TDF/FTC ). On Day 14, 24-hour intensive TMC125 pharmacokinetic sampling took place and fasting lipids were assessed. In the second part of the trial (Days 15-28) darunavir (DRV)/ritonavir (rtv) 800/100 mg qd was added to the regimen (Treatment B: TMC 125 + TDF/FTC + DRV/rtv). On Day 28, 24-hour intensive pharmacokinetic sampling for TMC125, DRV and ritonavir took place and fasting lipids were assessed. In the third part of the trial (Day 29-42), TMC125 was discontinued and subjects received treatment with DRV/rtv 800/100 mg q.d. and TDF/FTC FDC 300/200 mg qd (Treatment C: DRV/rtv + TDF/FTC).On Day 42, fasting lipids were assessed. Subjects discontinued or entered the optional open-label extension period DRV/rtv + TDF/FTC. TDF/FTC +/- TMC125 +/- DRV/Rtv Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but", "textAfterTable": "Period 2: \u00a0 Treatment B: TMC125 + TDF/FTC + DRV/Rtv \u00a0 \u00a0 TDF/FTC +/- TMC125 +/- DRV/Rtv \u00a0 STARTED \u00a0 \u00a0 21 \u00a0 COMPLETED \u00a0 \u00a0 21 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 Period 3: \u00a0 Treatment C: DRV/Rtv + TDF/FTC \u00a0 \u00a0 TDF/FTC +/- TMC125 +/- DRV/Rtv \u00a0 STARTED \u00a0 \u00a0 21 \u00a0 COMPLETED \u00a0 \u00a0 20 \u00a0 NOT COMPLETED \u00a0 \u00a0 1 \u00a0 Physician Decision \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Period 4: \u00a0 Optional Extension: DRV/Rtv + TDF/FTC", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}